Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study To Determine The Efficacy and Safety of Buprenorphine (as NTC-510) in Subjects With Pain Following Surgical Extraction of 1 or 2 Third Molars.

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study To Determine The Efficacy and Safety of Buprenorphine (as NTC-510) in Subjects With Pain Following Surgical Extraction of 1 or 2 Third Molars.

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 14 Jan 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Buprenorphine/naloxone (Primary) ; Buprenorphine
  • Indications Dental pain
  • Focus Therapeutic Use
  • Sponsors Ology Bioservices
  • Most Recent Events

    • 02 Oct 2017 According to a Ology Bioservices media release, Nanotherapeutics changed its name to Ology Bioservices.
    • 11 Apr 2016 Status changed from recruiting to discontinued because safety and efficacy after cohort 5 did not warrant further dose escalation
    • 04 Dec 2015 According to ClinicalTrials.gov record, the treatment table has been amended due to the addition of NTC-510A (Buprenorphine alone) and hence the patients no has also been increased.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top